Pressmeddelande

  • The first patient included in Australia in Isofol’s Phase 3 AGENT study

    GOTHENBURG, Sweden, January 24 2020 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL) today announced that the first…

    by
  • Patent approved in Japan for Isofol’s drug candidate arfolitixorin

    GOTHENBURG, Sweden, December 20, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL). A patent covering the Active…

    by
  • Patent detecting how patients respond to folate-based cancer treatment approved in the USA

    GOTHENBURG, Sweden, December 13, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announces the approval from…

    by
  • Isofol to Expand Global Phase 3 AGENT Trial in First-Line Metastatic Colorectal Cancer to Australia

    GOTHENBURG, Sweden, November 18, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced the successful completion…

    by
  • Isofol’s board appoints Dr. Jarl Ulf Jungnelius as new CEO of the company

    GOTHENBURG, Sweden, November 13, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced that the board…

    by
  • Isofol Receives Positive Feedback from PMDA in Japan, Expanding Ongoing Global Pivotal Phase 3 AGENT Trial in First Line Metastatic Colorectal Cancer

    GOTHENBURG, Sweden, October 18, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced the successful completion…

    by
  • ISOFOL ANNOUNCES THAT AN ABSTRACT HAS BEEN ACCEPTED FOR PRESENTATION AT THE 2019 ESMO CONGRESS

    GOTHENBURG, Sweden, September 12, 2019 - Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced that an abstract…

    by
  • Isofol Receives Clinical Use Patent Approval in the United States for Drug Candidate arfolitixorin

    GOTHENBURG, Sweden, June 25, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced approval of a…

    by
  • Isofol Receives Clinical Use Patent Approval in the United States for Drug Candidate arfolitixorin

    GOTHENBURG, Sweden, June 25, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced approval of a…

    by
  • Isofol’s drug candidate arfolitixorin receives clinical patent approval in the United States

    GOTHENBURG, Sweden, May 21, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced approval of a…

    by